*Submit your email address to receive conference udpates

BioTrinity 2007 featured five key deals including alliance and financing rounds of $50m and up

Wednesday 28 March 2007
09:35- Key Deals
Selected Key Deals from Leading Growth Companies including licensing deals or acquisitions of $300m and up. Chaired by Mike Ward, Senior Editor (Europe), BioCentury
09:35-09:55 Dr Alex Chanas - Pfizer Ltd, Licensing Director
"The role of the PowderMed acquisition in Pfizer Vaccines strategic development"

09:55-10:15 Dr Anker Lundemose - Executive VP, President (OSI) Prosidion, OSI Pharmaceuticals, Inc. President, Prosidion Limited   "Licensing of the Glucokinase Program for Diabetes to Eli Lilly"

10:15-10:30 Tony Longstaff, MD, MEPC Milton Park   "Reaching critical mass in Oxfordshire: Milton Park Bioscience Campus"

10:30-11:00 Coffee/tea break, Networking and Exhibits
(Sponsored by SEHTA)

Confirmed speakers please register as soon as possible

Submit your email address to receive conference updates

PROJECT PARTNERS

Project Partner: Thames Valley Life Science Network Project Partner: BioSpectrumAsia Project Partner: PharmaLicensing
Project Partner: London Biotechnology Network With a high number of biotech and pharmaceutical companies based in the county, the Kent bioscience sector is proud of its success in discovery and innovation found in its larger businesses, which co-exist with fledgling bioscience companies such as those found at the Kent Science Park in Sittingbourne. Project Partner: Surrey Enterprise Hub
BioProcess UK Drug Discovery Today covers not only drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed - Supporting Partners to BioTrinity MedNous
The STIMUNTRAN project has received European Regional Development Funding through the INTERREG III B Community Initiative NEW ENO Interreg IIIB North West Europe BioSpectrum